Table 5.
Locoregional relapse (LRR) free survival analysis (N = 263) (all patients).
| Parameters | N | N of events | Mean | 95% C.I. of mean | p value |
|---|---|---|---|---|---|
| Age (yrs) | 0.002 | ||||
| <50 | 160 | 11 (6.9) | 118.9 | 114.3–123.5 | |
| ≥50 | 103 | 20 (19.4) | 100.4 | 91.9–108.9 | |
| Initial tumor size (cm) | 0.640 | ||||
| <5 | 136 | 14 (10.3) | 114.9 | 108.9–120.9 | |
| ≥5 | 123 | 15 (12.2) | 109.4 | 103.0–115.9 | |
| Surgery type | 0.274 | ||||
| Mastectomy | 200 | 26 (13.0) | 111.2 | 105.7–116.6 | |
| BCS | 63 | 5 (7.9) | 117.8 | 110.3–125.5 | |
| ER | 0.843 | ||||
| Negative | 94 | 11 (11.7) | 113.0 | 105.2–120.7 | |
| Positive | 169 | 20 (11.8) | 110.9 | 105.5–116.2 | |
| PgR | 0.743 | ||||
| Negative | 124 | 15 (12.1) | 112.6 | 105.9–119.4 | |
| Positive | 139 | 16 (11.5) | 102.9 | 97.6–108.2 | |
| HER2 | 0.429 | ||||
| Negative | 168 | 18 (10.7) | 114.3 | 108.8–119.8 | |
| Positive | 95 | 13 (13.7) | 108.5 | 100.7–116.3 | |
| Subtype | 0.946 | ||||
| Luminal A | 23 | 2 (8.7) | 99.0 | 89.3–108.7 | |
| Luminal B (HER2 negative) | 96 | 11 (11.5) | 110.2 | 103.0–117.3 | |
| Luminal B (HER2 positive) | 50 | 7 (14) | 108.9 | 98.5–119.2 | |
| HER2 overexpression | 45 | 6 (13.3) | 106.6 | 95.3–117.9 | |
| Triple-negative | 49 | 5 (10.2) | 114.7 | 104.5–124.9 | |
| NAC cycles | 0.144 | ||||
| ≤4 | 256 | 29 (11.3) | 113.8 | 109.3–118.3 | |
| >4 | 7 | 2 (28.5) | 78.4 | 30.4–126.4 | |
| Pathology response | 0.044 | ||||
| pCR | 29 | 0 (0) | N/A | ||
| Non-pCR | 234 | 31 (13.2) | 111.5 | 106.4–116.5– |
N: number; Numbers in parentheses are percentages.
Abbreviations: BCS: breast-conserving surgery; CR: complete response; ER: estrogen receptor; HER-2: human epidermal growth factor receptor 2; NAC: neoadjuvant chemotherapy; pCR: pathological complete response; PgR: progesterone receptor.